Medicare Coverage For FOBs: MedPAC Weighs Least Costly Alternative, Coding Options
This article was originally published in The Pink Sheet Daily
Executive Summary
The Medicare Payment Advisory Commission is taking up payment issues for follow-on biologics as legislation establishing a regulatory pathway for approving such products gathers momentum in Congress.
You may also be interested in...
MedPAC Considers Part D Changes To Enhance Savings From Follow-On Biologics
At a recent meeting, the advisory group discussed the possibility that under the current Part D structure, the amount Medicare might save from follow-on biologics may be limited.
MedPAC Considers Part D Changes To Enhance Savings From Follow-On Biologics
At a recent meeting, the advisory group discussed the possibility that under the current Part D structure, the amount Medicare might save from follow-on biologics may be limited.
Biosimilar Interchangeability Does Not Create Substitution Under House Bills
While biosimilars legislation is seen as a means of lowering health care costs, interchangeability provisions in House bills creating a biosimilars approval pathway would not be enough to allow automatic substitution at the pharmacy level - the route to the highest savings